-
Neurofeedback and epilepsy: Renaissance of an old self-regulation method? Rev. Neurol. (IF 3.0) Pub Date : 2024-03-13 A. Marchi, R. Guex, M. Denis, N. El Youssef, F. Pizzo, C.-G. Bénar, F. Bartolomei
Neurofeedback is a brain-computer interface tool enabling the user to self-regulate their neuronal activity, and ultimately, induce long-term brain plasticity, making it an interesting instrument to cure brain disorders. Although this method has been used successfully in the past as an adjunctive therapy in drug-resistant epilepsy, this approach remains under-explored and deserves more rigorous scientific
-
Inflammatory sensory neuronopathies Rev. Neurol. (IF 3.0) Pub Date : 2024-03-11 J.-C. Antoine
Inflammatory sensory neuronopathies are rare disorders mediated by dysimmune mechanisms targeting sensory neurons in the dorsal root ganglia. They constitute a heterogeneous group of disorders with acute, subacute, or chronic courses, and occur with cancer, systemic autoimmune diseases, notably Sjögren syndrome, and viral infections but a noticeable proportion of them remains isolated. Identifying
-
Brain MRI in status epilepticus: Relevance of findings Rev. Neurol. (IF 3.0) Pub Date : 2024-03-11 T. Bonduelle, M. Ollivier, A. Gradel, J. Aupy
Status epilepticus (SE) represents one of the most common neurological emergencies, associated with high mortality and an important risk of functional sequelae in survivors. Magnetic resonance imaging (MRI) offers the possibility of early and noninvasive observation of seizure-induced parenchymal disturbances secondary to the epileptic process. In the present review, we propose a descriptive and comprehensive
-
Drug-resistant juvenile myoclonic epilepsy: A literature review Rev. Neurol. (IF 3.0) Pub Date : 2024-03-08 A. Nica
The ILAE's Task Force on Nosology and Definitions revised in 2022 its definition of juvenile myoclonic epilepsy (JME), the most common idiopathic generalized epilepsy disorder, but this definition may well change again in the future. Although good drug response could almost be a diagnostic criterion for JME, drug resistance (DR) is observed in up to a third of patients. It is important to distinguish
-
Influence of intracranial hemorrhage on clinical outcome in acute vertebrobasilar artery occlusion undergoing endovascular treatment Rev. Neurol. (IF 3.0) Pub Date : 2024-03-06 N. Li, M. Hong, X. Chen, W. Sun, Z. Chen, L. Chen, S. Li, H. Ge, F. Peng
The effect of intracranial hemorrhage (ICH) on the outcome of patients with large-vessel occlusion undergoing endovascular treatment (EVT) has mainly focused on the anterior circulation. Knowledge of the relationship between ICH and outcomes in patients with acute vertebrobasilar artery occlusion (VBAO) receiving EVT is limited. We aimed to assess whether ICH is a prognostic marker for acute VBAO following
-
Prevalence of multiple system atrophy: A literature review Rev. Neurol. (IF 3.0) Pub Date : 2024-03-06 S, ., , K, a, p, l, a, n
This paper aims to provide a literature overview on multiple system atrophy (MSA) prevalence in European and other pan-European populations. A literature search (PubMed, EMBASE) was performed through 2022 to identify published studies on MSA prevalence in European countries. Of these search results, titles and abstracts were screened for relevance. A standardized assessment tool was used for systematically
-
Étienne Lancereaux (1829–1910), clinician and neuropathologist Rev. Neurol. (IF 3.0) Pub Date : 2024-03-05 O, ., , W, a, l, u, s, i, n, s, k, i
-
Safety and efficacy of reperfusion therapies in acute ischemic stroke related to left ventricular thrombus: A retrospective cohort study Rev. Neurol. (IF 3.0) Pub Date : 2024-03-01 P. Clottes, T. Bochaton, L. Mechtouff, L. Derex, T.-H. Cho, J. Fontaine, L. Rascle, Y. Berthezène, C. Amaz, H. Thibault, C. Bergerot, N. Nighoghossian, E. Ong
Left ventricular thrombus (LVT) is a source of cardiogenic embolic stroke. Conflicting data exist in the literature regarding the utilization of intravenous thrombolysis (IVT) at the acute phase of stroke in presence of LVT. We sought to assess the efficacy and safety of reperfusion therapies (IVT and/or thrombectomy) in patients with LVT. We retrospectively analyzed patients with acute ischemic stroke
-
Prevalence of multiple sclerosis in France in 2021: Data from the French health insurance database Rev. Neurol. (IF 3.0) Pub Date : 2024-02-28 C. Pierret, M. Mainguy, E. Leray
France is among the countries with high prevalence of multiple sclerosis (MS). The most recent estimates are from 2012 and need to be updated because MS prevalence has increased worldwide. To estimate MS prevalence in France on December 31, 2021 and to describe the characteristics of the French MS population using data from the French national health insurance database (SNDS). Persons with MS (PwMS)
-
The landscape of drug resistant absence seizures in adolescents and adults: Pathophysiology, electroclinical spectrum and treatment options Rev. Neurol. (IF 3.0) Pub Date : 2024-02-26 G. Daquin, F. Bonini
The persistence of typical absence seizures (AS) in adolescence and adulthood may reduce the quality of life of patients with genetic generalized epilepsies (GGEs). The prevalence of drug resistant AS is probably underestimated in this patient population, and treatment options are relatively scarce. Similarly, atypical absence seizures in developmental and epileptic encephalopathies (DEEs) may be unrecognized
-
Care of pharmaco-resistant absence seizures in childhood Rev. Neurol. (IF 3.0) Pub Date : 2024-02-21 M. Le Roux, N. Benallegue, S. Gueden, M. Rupin-Mas, P. Van Bogaert
In childhood absence epilepsy, pharmaco-resistance occurs in 20–30% of patients. In that situation, glucose transporter type 1 deficiency has to be ruled out, especially if absences started before the age of four years and if neurological signs are present. If ethosuximide, valproate and lamotrigine have failed in monotherapy or in association, there are currently no valuable therapeutic options. The
-
Antoine-Barthélemy Clot, known as Clot-Bey (1793–1868), and spinitis in 1820 Rev. Neurol. (IF 3.0) Pub Date : 2024-02-08 O. Walusinski
-
-
Does the guidance method affect the doses of botulinum toxin in writer's cramp? Rev. Neurol. (IF 3.0) Pub Date : 2024-02-08 A. Kreisler, K. Watel, L. Defebvre, L. Mortain, A. Duhamel
-
The neurologist Henri Hallopeau (1842–1919), a famous dermatologist Rev. Neurol. (IF 3.0) Pub Date : 2024-02-06 O. Walusinski
-
Woodhouse-Sakati syndrome: A review Rev. Neurol. (IF 3.0) Pub Date : 2024-02-05 C. Messina
Neurodegeneration with brain iron accumulation (NBIA) is a rare and inherited spectrum of movement disorders caused by mutations affecting the function of proteins that participate in the homeostasis of tissue metals such as iron or copper and other metabolic pathways, although the precise function of the proteins encoded are not always known. Woodhouse-Sakati Syndrome (WSS) is one of the rarest NBIAs
-
The effect of gabapentin and pregabalin on agitation in dementia: Case series of ten patients Rev. Neurol. (IF 3.0) Pub Date : 2024-02-03 M. Kandemir Yilmaz
Neurobehavioral symptoms are difficult to manage in dementia patients. Agitation may negatively impact patients’ health and increase the caregiver burden. Pharmacological and non-pharmacological approaches can be adopted to reduce agitation. Recently, positive effects of gabapentinoids have been identified in case reports with promising results and good safety profiles. This observational study was
-
Neurodystrophic hand dermatitis – Sannino-Barduagni syndrome Rev. Neurol. (IF 3.0) Pub Date : 2024-02-03 A. Demas, T. Apard, A.-L. Bedat-Millet, T. Maisonobe
Abstract not available
-
Sensorimotor deficit: To worm information out of white blood cell count! Rev. Neurol. (IF 3.0) Pub Date : 2024-02-03 M. Camard, C. Labeyrie, S. Bessis, G. Beaudonnet, D. Beauvais
Abstract not available
-
Antibody responses to SARS-CoV-2 vaccines in neuromuscular disorders may depend on their etiology and current drug treatment Rev. Neurol. (IF 3.0) Pub Date : 2024-02-03 J. Finsterer
Abstract not available
-
-
-
Unveiling autonomic failure in synucleinopathies: Significance in diagnosis and treatment Rev. Neurol. (IF 3.0) Pub Date : 2024-01-11 G. Clement, G. Cavillon, F. Vuillier, M. Bouhaddi, M. Béreau
Autonomic failure is frequently encountered in synucleinopathies such as multiple system atrophy (MSA), Parkinson's disease (PD), Lewy body disease, and pure autonomic failure (PAF). Cardiovascular autonomic failure affects quality of life and can be life threatening due to the risk of falls and the increased incidence of myocardial infarction, stroke, and heart failure. In PD and PAF, pathogenic involvement
-
Anatomy and physiology of the autonomic nervous system: Implication on the choice of diagnostic/monitoring tools in 2023 Rev. Neurol. (IF 3.0) Pub Date : 2024-01-03 F. Roche, V. Pichot, L. Mouhli-Gasmi, M. Monier, J.-C. Barthélémy, M. Berger, S. Celle, F. Chouchou
The autonomic nervous system (ANS) harmoniously regulates all internal organic functions (heart rate, blood pressure, vasomotion, digestive tract motility, endocrinal secretions) and adapts them to the needs. It's the control of so-called vegetative functions, which allows homeostasis but also allostasis of our body. ANS is divided into two systems often understood as antagonistic and complementary:
-
What you feel is not always what you’ve got. Jean Lhermitte (1877–1959) and the phantom limb phenomenon Rev. Neurol. (IF 3.0) Pub Date : 2023-12-22 E. Drouin, L. Tatu, P. Hautecoeur
Jean Lhermitte (1877–1959), the French neurologist and psychiatrist, is most often associated with the sign he described in three patients with multiple sclerosis, back in 1927. In 1937, Lhermitte analytically studied a series of 28 amputees experiencing phantom limb sensations further to amputations dating between 1891 and 1934. After having described the main clinical characteristics of this unpublished
-
Autonomic nervous system involvement in autoimmune encephalitis and paraneoplastic neurological syndromes Rev. Neurol. (IF 3.0) Pub Date : 2023-12-22 M. Villagrán-García, A. Farina, L. Campetella, J. Arzalluz-Luque, J. Honnorat
In autoimmune neurological diseases, the autonomic nervous system can be the primary target of autoimmunity (e.g. autoimmune autonomic ganglionopathy), or, more frequently, be damaged together with other areas of the nervous system (e.g. Guillain-Barré syndrome). Patients with autoimmune encephalitis and paraneoplastic neurological syndromes (PNS) often develop dysautonomia; however, the frequency
-
Acute posterior ischemic optic neuropathy associated with a hypertensive crisis Rev. Neurol. (IF 3.0) Pub Date : 2023-12-21 E. Sole Cruz, N. Stolowy, R. Attia, B. Audoin, S. Demortière
Abstract not available
-
An overview on pure autonomic failure Rev. Neurol. (IF 3.0) Pub Date : 2023-12-20 A. Pavy-Le Traon, A. Foubert-Samier, M. Fabbri
Pure autonomic failure (PAF) is a neurodegenerative disease affecting the sympathetic component of the autonomic nervous system and presenting as orthostatic hypotension (OH). It is a rare, sporadic disease of adults. Although OH is the primary symptom, the autonomic dysfunction may be more generalised, leading to genitourinary and intestinal dysfunction and sweating disorders. Autonomic symptoms in
-
Is there a place for EMDR in neurology? Rev. Neurol. (IF 3.0) Pub Date : 2023-12-20 H. Magne
Abstract not available
-
The gut-brain axis in Parkinson's disease Rev. Neurol. (IF 3.0) Pub Date : 2023-12-20 B. Bonaz
There is a bi-directional communication between the gut, including the microbiota, and the brain through the autonomic nervous system. Accumulating evidence has suggested a bidirectional link between gastrointestinal inflammation and neurodegeneration, in accordance with the concept of the gut-rain axis. An abnormal microbiota-gut-brain interaction contributes to the pathogeny of Parkinson's disease
-
Orthostatic hypotension: Review and expert position statement Rev. Neurol. (IF 3.0) Pub Date : 2023-12-19 E. Vidal-Petiot, A. Pathak, J.-P. Azulay, A. Pavy-Le Traon, O. Hanon
Orthostatic hypotension is defined as a drop in systolic blood pressure of at least 20 mmHg or a drop in diastolic blood pressure of at least 10 mmHg within 3 minutes of standing. It is a common disorder, especially in high-risk populations such as elderly subjects and patients with neurological diseases, and is associated with markedly increased morbidity and mortality. Its management can be challenging
-
Safinamide for pain management in patients with Parkinson's disease Rev. Neurol. (IF 3.0) Pub Date : 2023-12-15 D. Abilashimova, M. Aubakirova, Y. Abdildin, D. Viderman
Introduction Pain is often neglected in Parkinson's disease (PD), although it impacts most PD patients. While the mechanism of pain in PD is still being studied, various pharmacological, interventional, and alternative treatment options have been offered for pain relief. Safinamide, a recently approved drug for PD, has shown promising results in improving pain in patients with PD. Several clinical
-
In young patients with stroke of undetermined etiology, large vessel occlusions are less frequent in the group with high-risk patent foramen ovale Rev. Neurol. (IF 3.0) Pub Date : 2023-12-14 A. Ter Schiphorst, A. Lippi, L. Corti, I. Mourand, P. Prin, A. Agullo, F. Cagnazzo, J.-C. Macia, C. Arquizan
Introduction Patent foramen ovale (PFO) is present in a significant proportion of young patients with stroke of undetermined etiology, but is not always causal. Therefore, classifications (RoPE, PASCAL) have been developed to determine the probability that PFO is the stroke cause. However, the presence of an initial arterial occlusion as a prediction factor was not studied when these classifications
-
Focused ultrasounds: What is their future in epileptology? A critical review Rev. Neurol. (IF 3.0) Pub Date : 2023-12-12 M.D. Maliia, A. Nica, J. Baxter, M.V. Corniola
High intensity focused ultrasounds (HIFU) are being increasingly advocated as a useful tool in the management of focal drug-resistant epilepsy. Our aim was to review current literature on the topic and perform an inventory of open trials assessing HIFU effectiveness and safety in epilepsy management. To do so, a review was conducted and yielded one prospective clinical trials, two case reports and
-
Management of lower urinary tract symptoms in Parkinsonian disorders Rev. Neurol. (IF 3.0) Pub Date : 2023-12-12 C. Guillot-Tantay
Introduction The aim of the study was to present a narrative review of the literature on the management of lower urinary tract symptoms (LUTS) in patients presenting Parkinsonian disorders (PD). Material and methods We carried out a literature search in PubMed and Embase database, without time restriction. We used keywords and free-text words around “Parkinsonian disorders” AND “lower urinary tracts
-
SWI versus GRE-T2*: Assessing cortical superficial siderosis in advanced cerebral amyloid angiopathy Rev. Neurol. (IF 3.0) Pub Date : 2023-12-06 P. Assis Lopes, N. Raposo, A. Charidimou, M.C. Zanon Zotin, M. Edip Gurol, S. Greenberg, A. Viswanathan
Background and purpose Cortical superficial siderosis (cSS) is a key neuroimaging marker of cerebral amyloid angiopathy (CAA) detected on blood-sensitive magnetic resonance imaging (MRI). We aimed to assess cSS in advanced CAA patients and explore differences in its evaluation between susceptibility weighted imaging (SWI) and gradient recalled echo-T2* (GRE-T2*). Materials and methods Neuroimaging
-
Professor Alan B. Scott (1932–2021): “The inventor of Botox” Rev. Neurol. (IF 3.0) Pub Date : 2023-12-05 M.-H. Marion
Abstract not available
-
Impact of anti-PD-1 therapy in a melanoma patient with paraneoplastic anti-ITPR1 encephalitis Rev. Neurol. (IF 3.0) Pub Date : 2023-12-06 F. Brunet-Possenti, C. Birzu, L. Deschamps, S. Hacein-Bey-Abina, D. Psimaras, P. Chrétien
Abstract not available
-
Seizure recurrences in generalized convulsive status epilepticus under sedation: What are its predictors and its impact on outcome? Rev. Neurol. (IF 3.0) Pub Date : 2023-12-04 M. Dhoisne, A. Delval, D. Mathieu, A. Mazeraud, L. Bournisien, P. Derambure, R. Tortuyaux
Background Management of status epilepticus (SE) is focused on the early seizure termination. Refractory SE is an indication for sedation in patients with SE, but up to 75% of patients may be ventilated due to a neurological or respiratory failure. In patients requiring sedation, the clinical assessment is not sufficient to assess seizure control. Identifying those at risk of recurrent seizures could
-
Neurological disorders related to recreational nitrous oxide abuse: Two sides of the same coin Rev. Neurol. (IF 3.0) Pub Date : 2023-12-04 R. Delsanti, C. Arnaud, G. Defer
Abstract not available
-
Crossed sympathetic pathways in 3 cases of Harlequin syndrome Rev. Neurol. (IF 3.0) Pub Date : 2023-12-05 M. Cheval, A. de Liege, C. Benoit, B. Garcin, B. Degos
Abstract not available
-
Epileptic seizures in patients with primary central nervous system lymphoma: A systematic review Rev. Neurol. (IF 3.0) Pub Date : 2023-12-01 O. Aboubakr, C. Houillier, S. Choquet, S. Dupont, K. Hoang-Xuan, B. Mathon
Background Primary central nervous system lymphoma (PCNSL) accounts for less than 5% of primary brain tumors. Epileptic seizures are a common manifestation of brain tumors; however, literature on the prevalence, characteristics, and oncological implications of seizures in patients with PCNSL is limited, and the management of antiepileptic drugs (AEDs) is unclear. This review aimed to summarize the
-
Stroke-like manifestations of angioedema: A case report and the identification of a novel mutation Rev. Neurol. (IF 3.0) Pub Date : 2023-12-01 J.-D. Karam, X. Boulu, G. Hardy, Y. Buron
Abstract not available
-
Evaluation of quality of life's prognostic factors in people with functional seizures Rev. Neurol. (IF 3.0) Pub Date : 2023-11-30 P. Capitaine, B. Thomas, A. Gradel, T. Ferté, O. Branchard, E. Frison, V. Renaudeau, J. Aupy
Aims Functional non-epileptic seizures significantly impact the quality of life of patients. We aimed to identify prognostic factors associated with the quality of life in individuals with functional non-epileptic seizures. Subjects and methods Adult patients diagnosed with definite or documented functional seizures based on LaFrance's criteria (n = 72) were enrolled at the time of diagnosis. Quality
-
Importance of glucose and its metabolism in neurodegenerative disorder, as well as the combination of multiple therapeutic strategies targeting α-synuclein and neuroprotection in the treatment of Parkinson's disease Rev. Neurol. (IF 3.0) Pub Date : 2023-11-30 A.H.H. Siddique, P.P. Kale
According to recent findings, Phosphoglycerate Kinase 1 (pgk-1) enzyme is linked to Parkinson's disease (PD). Mutations in the PGK-1 gene lead to decreases in the pgk-1 enzyme which causes an imbalance in the levels of energy demand and supply. An increase in glycolytic adenosine triphosphate (ATP) production would help alleviate energy deficiency and sustain the acute energetic need of neurons. Neurodegeneration
-
Outcome of stroke patients eligible to mechanical thrombectomy managed by spoke center, primary stroke center or comprehensive stroke center in the East of France Rev. Neurol. (IF 3.0) Pub Date : 2023-11-29 W. Abou Loukoul, S. Richard, G. Mione, S. Finitsis, A.-L. Derelle, F. Zhu, L. Liao, R. Anxionnat, M. Douarinou, L. Humbertjean, B. Gory
Background and purpose Patients with suspected stroke are referred to the nearest hospital and are managed either in a spoke center (SC), a primary stroke center (PSC), or a comprehensive stroke center (CSC) in order to benefit from early intravenous thrombolysis (IVT). In case of large vessel occlusion (LVO), mechanical thrombectomy (MT) is only performed in the CSC, whereas the effectiveness of MT
-
-
Retraction notice to “Ataxie spinocérébelleuse de type 31 (SCA 31) : revue de la littérature à la lumière du premier diagnostic chez un patient caucasien ; un phénotype différent chez les patients non-japonais ?”[NEUROL 178S (2022) S46] Rev. Neurol. (IF 3.0) Pub Date : 2023-12-01 J. Saucier, A.-Q. Mohammad, B.A. Mouna, L. Chamard Witkowski
Abstract not available
-
-
Fostering patient engagement through the co-design of seizure detection and monitoring technologies: A roadmap for collaboration between research and development Rev. Neurol. (IF 3.0) Pub Date : 2023-11-30 E. Monfort, P. Latour
The large number of technological developments suggests that patients with epilepsy can be better supported in the management of their seizures, especially when their condition is drug resistant. Patients and their caregivers, who are generally supportive of seizure detection and monitoring technologies, can provide relevant information to improve their effectiveness. We propose a comprehensive co-design
-
Neuropsychological assessment in pediatric epilepsy surgery: A French procedure consensus Rev. Neurol. (IF 3.0) Pub Date : 2023-11-08 V. Laguitton, M. Boutin, H. Brissart, D. Breuillard, M. Bilger, N. Forthoffer, V. Guinet, S. Hennion, C. Kleitz, H. Mirabel, C. Mosca, S. Pradier, S. Samson, V. Voltzenlogel, M. Planton, M. Denos, C. Bulteau
Neuropsychological assessment is a mandatory part of the pre- and post-operative evaluation in pediatric epilepsy surgery. The neuropsychology task force of the ILAE - French Chapter aims to define a neuropsychological procedure consensus based on literature review and adapted for French practice. They performed a systematic review of the literature published between 1950 and 2023 on cognitive evaluation
-
-
-
Epidemiology of myasthenia gravis in France: A retrospective claims database study (STAMINA) Rev. Neurol. (IF 3.0) Pub Date : 2023-11-07 E. Salort-Campana, P. Laforet, G. de Pouvourville, A. Crochard, G. Chollet, C. Nevoret, C. Emery, S. Bouée, C. Tard
The objectives of this observational study were to report the incidence and prevalence of myasthenia gravis (MG) in France, describe patients’ characteristics and treatment patterns, and estimate mortality. A historical cohort analysis was performed using the French National Health Data System (SNDS) database between 2008 and 2020. Patients with MG were identified based on ICD-10 codes during hospitalization
-
Erratum to “REM sleep function: Mythology vs. reality” [Rev. Neurol. 179 (2023) 643–648] Rev. Neurol. (IF 3.0) Pub Date : 2023-11-03 J.M. Siegel
Abstract not available
-
Directional deep brain stimulation is useful to correct the misplacement of intracerebral electrode after reimplantation Rev. Neurol. (IF 3.0) Pub Date : 2023-11-01 G. Costentin, S. Derrey, D. Maltête
Abstract not available
-
Is internal retinal thickness an early marker of Alzheimer's and Lewy body diseases? Rev. Neurol. (IF 3.0) Pub Date : 2023-11-02 M. Singlas, T.H.C. Tran, W. Boucenna, M. Diouf, O. Godefroy
Abstract not available
-
Mediterranean-like diets in multiple sclerosis: A systematic review Rev. Neurol. (IF 3.0) Pub Date : 2023-10-28 H. Abbasi, F. Shakouri, R. Mosaddeghi-Heris, E. Gholipour-Khalili, F. Jahanshahlou, S. Sanaie, A. Naseri, M. Talebi
Background Mediterranean-like diet is an anti-inflammatory diet with high-fiber consumption and lower intake of saturated fatty acids which is proposed to have beneficial effects in patients with multiple sclerosis (MS). This investigation aims to explore the impacts of this style of diet on people living with MS, based on clinical evidence. Methods This study was conducted following the 2020 version
-
Spinal and bulbar muscular atrophy: Kennedy's disease and its first description by Hiroshi Kawahara in 1897 Rev. Neurol. (IF 3.0) Pub Date : 2023-10-26 H.A.G. Teive, L. Coutinho, F.E.C. Cardoso, S. Tsuji
Abstract not available
-
Vanishing white matter in multiple mitochondrial dysfunction syndrome-2 due to compound heterozygosity for novel BOLA3 variants Rev. Neurol. (IF 3.0) Pub Date : 2023-10-26 J. Finsterer
Abstract not available